Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide (CGRP) – Overview
Calcitonin Gene Related Peptide (CGRP) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Calcitonin Gene Related Peptide (CGRP) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) – Companies Involved in Therapeutics Development
Acherx LLC
AfaSci Inc
Eli Lilly and Co
H. Lundbeck AS
Kissei Pharmaceutical Co Ltd
Nepsone ehf
Pharmnovo AB
Shandong Boan Biotechnology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Teva Pharmaceutical Industries Ltd
Vaxxinity Inc
Calcitonin Gene Related Peptide (CGRP) – Drug Profiles
ACX-101 – Drug Profile
Product Description
Mechanism Of Action
History of Events
AFAP-3 – Drug Profile
Product Description
Mechanism Of Action
History of Events
eptinezumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
fremanezumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
galcanezumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Inhibit CGRP for Medullary Thyroid Cancer – Drug Profile
Product Description
Mechanism Of Action
History of Events
JS-010 – Drug Profile
Product Description
Mechanism Of Action
KCZ-1279 – Drug Profile
Product Description
Mechanism Of Action
Monoclol Antibody to Inhibit CGRP for Migraine – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit CGRP for Psoriasis – Drug Profile
Product Description
Mechanism Of Action
UB-313 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Calcitonin Gene Related Peptide (CGRP) – Dormant Products
Calcitonin Gene Related Peptide (CGRP) – Discontinued Products
Calcitonin Gene Related Peptide (CGRP) – Product Development Milestones
Featured News & Press Releases
Jun 24, 2022: Teva announces promising interim results from its study PEARL, about the impact of AJOVY (fremanezumab)
Jun 16, 2022: Results from the DELIVER study with Vyepti has been published in a top-ranking medical jourl
Jun 15, 2022: Otsuka obtains approval in Japan for Auto-Injector dosage form for AJOVY subcutaneous injection 225 mg for preventive treatment of migraine
Jun 09, 2022: Lundbeck to present data on VYEPTI (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, furthering clinical and real-world evidence for migraine prevention
Jun 09, 2022: Teva to present latest data on AJOVY (fremanezumab-vfrm) injection at the 2022 American Headache Society Annual Meeting
Jun 09, 2022: New real-world data evaluating AJOVY (fremanezumab-vfrm) injection use in patients with migraine presented at 2022 American Headache Society Annual Meeting
May 17, 2022: Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Cada’s AJOVY (fremanezumab), for the preventive treatment of migraine in adults
Apr 02, 2022: Lundbeck to present new data at AAN 2022 adding to clinical evidence regarding VYEPTI
Apr 01, 2022: Teva to present new alyses of AJOVY (fremanezumab-vfrm) injection and AUSTEDO (deutetrabezine) tablets at 2022 American Academy of Neurology Annual Meeting
Mar 02, 2022: Teva Cada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Qu?bec, Veteran Affairs Cada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY (fremanezumab) for the preventive treatment of migraine in adults
Jan 24, 2022: Vyepti (eptinezumab) approved by the EU Commission for the preventive treatment of migraine in adults
Nov 19, 2021: Lilly begins enrolment in Phase IV trial of Emgality for migraine prevention
Nov 12, 2021: Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migraine in adults
Nov 08, 2021: From clinical trial efficacy to real-world effectiveness first AJOVY (fremanezumab) data from European Real World Evidence Program
Nov 01, 2021: Lundbeck reports positive results for Vyepti(eptinezumab) from the DELIVER study in patients with migraine and prior preventive treatment failures
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Acherx LLC, 2022
Pipeline by AfaSci Inc, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by H. Lundbeck AS, 2022
Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Pipeline by Nepsone ehf, 2022
Pipeline by Pharmnovo AB, 2022
Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Pipeline by Vaxxinity Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022